https://scholars.lib.ntu.edu.tw/handle/123456789/539752
標題: | Systemic co-delivery of doxorubicin and siRNA using nanoparticles conjugated with EGFR-specific targeting peptide to enhance chemotherapy in ovarian tumor bearing mice | 作者: | Liu C.W. WEN-JEN LIN |
關鍵字: | Doxorubicin; Epidermal growth factor receptor; Heptapeptide; Nanoparticles; siRNA | 公開日期: | 2013 | 卷: | 15 | 期: | 10 | 起(迄)頁: | 1956 | 來源出版物: | Journal of Nanoparticle Research | 摘要: | This aim of this study was to develop peptide-conjugated nanoparticles (NPs) for systemic co-delivery of siRNA and doxorubicin to enhance chemotherapy in epidermal growth factor receptor (EGFR) high-expressed ovarian tumor bearing mice. The active targeting NPs were prepared using heptapeptide-conjugated poly(d,l-lactic-co-glycolic acid)-poly(ethylene glycol). The particle sizes of peptide-free and peptide-conjugated NPs were 159.3 ± 32.5 and 184.0 ± 52.9 nm, respectively, with zeta potential -21.3 ± 3.8 and -15.3 ± 2.8 mV. The peptide-conjugated NPs uptake were more efficient in EGFR high-expressed SKOV3 cells than in EGFR low-expressed HepG2 cells due to heptapeptide specificity. The NPs were used to deliver small molecule anticancer drug (e.g., doxorubicin) and large molecule genetic agent (e.g., siRNA). The IC50 of doxorubicin-loaded peptide-conjugated NPs (0.09 ± 0.06 μM) was significantly lower than peptide-free NPs (5.72 ± 2.64 μM). The similar result was observed in siRNA-loaded NPs. The peptide-conjugated NPs not only served as a nanocarrier to efficiently deliver doxorubicin and siRNA to EGFR high-expressed ovarian cancer cells but also increased the intracellular accumulation of the therapeutic agents to induce assured anti-tumor growth effect in vivo. ? 2013 Springer Science+Business Media Dordrecht. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84887010960&doi=10.1007%2fs11051-013-1956-z&partnerID=40&md5=7690e1eadbfcb93703a3d32cab419959 https://scholars.lib.ntu.edu.tw/handle/123456789/539752 |
ISSN: | 13880764 | DOI: | 10.1007/s11051-013-1956-z | SDG/關鍵字: | Chemotherapy; Controlled drug delivery; Mammals; Molecules; Nanoparticles; Peptides; Polyethylene glycols; Tumors; Doxorubicin; Epidermal growth factor receptors; Heptapeptides; Intracellular accumulation; Ovarian cancer cells; Poly(D , L-lactic-co-glycolic acid); siRNA; Therapeutic agents; Targeted drug delivery; 1,2 dioleoyl 3 trimethylammoniopropane; doxorubicin; epidermal growth factor receptor; heptapeptide; macrogol; nanocarrier; nanoconjugate; polyglactin; small interfering RNA; animal experiment; animal model; antineoplastic activity; article; cancer chemotherapy; cancer gene therapy; cancer inhibition; cell strain HepG2; controlled study; drug accumulation; drug conjugation; drug cytotoxicity; drug delivery system; drug specificity; drug uptake; endocytosis; female; gene delivery system; gene expression; gene targeting; IC 50; in vivo study; mouse; nonhuman; ovary tumor; particle size; priority journal; protein expression; protein targeting; tumor cell line; zeta potential |
顯示於: | 藥學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。